Press release
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in
About this update from Geron Corporation
[{"type":"text","content":"\nAchieved $47.2 million in RYTELO® net product revenue in Q3 2025 \n\nCompleted enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis\n\nStrengthened leadership team with appointment of Chief Commercial Officer and additional key executives\n\nAnnounced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting \n\nCompany to host conference call and webcast today, November 5, at 8:00 a.m. ET \n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights.\n\n\"The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the potential to significantly impact the treatment paradigm. There is work ahead of us to fully maximize the value of this therapy and ensure RYTELO reaches more patients,” said Harout Semerjian, President and Chief Executive Officer of Geron. “Geron is positioned, with our realigned leadership team, to strengthen commercial execution, increase both physician and patient awareness, and drive RYTELO sales in the U.S. We look forward to presenting meaningful data at ASH, enhancing our partnerships with the MDS community and conducting the interim analysis for the IMpactMF trial. Our actions are focused on creating value for our patients and shareholders.”\n\nRecent Business Highlights\n\nRYTELO\n\n\nAchieved net product revenue of $47.2 million in the third quarter of 2025.\n\n\nDemand was down 3% quarter-over-quarter, with opportunities to elevate brand awareness and clinical value communications.\n\n\nNumber of ordering accounts is now approximately 1,150, an increase of approximately 150 quarter-over-quarter.\n\n\n\n\nIncreased RYTELO presence at major hematology forums, such as the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting.\n\n\nAnnounced that two abstracts highlighting data from the IMerge clinical trial in lower-risk MDS were accepted for presentation at the ASH 2025 Annual Meeting, including one oral presentation on the potential correlation between imetelstat clinical response rates and treatment-emergent cytopenias.\n\n...